AU2014290598B2 - Azaindole compounds, synthesis thereof, and methods of using the same - Google Patents

Azaindole compounds, synthesis thereof, and methods of using the same Download PDF

Info

Publication number
AU2014290598B2
AU2014290598B2 AU2014290598A AU2014290598A AU2014290598B2 AU 2014290598 B2 AU2014290598 B2 AU 2014290598B2 AU 2014290598 A AU2014290598 A AU 2014290598A AU 2014290598 A AU2014290598 A AU 2014290598A AU 2014290598 B2 AU2014290598 B2 AU 2014290598B2
Authority
AU
Australia
Prior art keywords
methyl
pct
hydrogen
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014290598A
Other languages
English (en)
Other versions
AU2014290598A1 (en
Inventor
Monalisa Chatterji
Maruti N. Naik
Shahul Hameed Peer Mohamed
Radha K. Shandil
Vikas Narayan Shinde
Pravin S. Shirude
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FOUNDATION FOR NEGLECTED DISEASE RESEARCH
Global Alliance for TB Drug Development
Original Assignee
Foundation For Neglected Disease Res
Global Alliance for TB Drug Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foundation For Neglected Disease Res, Global Alliance for TB Drug Development filed Critical Foundation For Neglected Disease Res
Publication of AU2014290598A1 publication Critical patent/AU2014290598A1/en
Assigned to FOUNDATION FOR NEGLECTED DISEASE RESEARCH, GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT reassignment FOUNDATION FOR NEGLECTED DISEASE RESEARCH Amend patent request/document other than specification (104) Assignors: ASTRAZENECA AB, FOUNDATION FOR NEGLECTED DISEASE RESEARCH
Application granted granted Critical
Publication of AU2014290598B2 publication Critical patent/AU2014290598B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2014290598A 2013-07-17 2014-07-10 Azaindole compounds, synthesis thereof, and methods of using the same Active AU2014290598B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3196CH2013 2013-07-17
IN3196/CHE/2013 2013-07-17
PCT/US2014/046100 WO2015009525A1 (en) 2013-07-17 2014-07-10 Azaindole compounds, synthesis thereof, and methods of using the same

Publications (2)

Publication Number Publication Date
AU2014290598A1 AU2014290598A1 (en) 2016-02-11
AU2014290598B2 true AU2014290598B2 (en) 2018-11-08

Family

ID=51261257

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014290598A Active AU2014290598B2 (en) 2013-07-17 2014-07-10 Azaindole compounds, synthesis thereof, and methods of using the same

Country Status (10)

Country Link
US (1) US9163020B2 (enExample)
EP (1) EP3021947B1 (enExample)
JP (1) JP6366709B2 (enExample)
KR (1) KR102301753B1 (enExample)
CN (1) CN105636646B (enExample)
AU (1) AU2014290598B2 (enExample)
CA (1) CA2918487C (enExample)
EA (1) EA028611B1 (enExample)
ES (1) ES2644025T3 (enExample)
WO (1) WO2015009525A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US11173113B2 (en) 2017-12-06 2021-11-16 Prollergy Corporation Composition and method for reducing allergic response
RU2702224C2 (ru) * 2018-03-29 2019-10-07 Общество С Ограниченной Ответственностью "Мт-Медикалс" Производные фенил формамидина, обладающие антимикобактериальной активностью
WO2019239382A1 (en) 2018-06-15 2019-12-19 Cadila Healthcare Limited Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria
WO2020188405A1 (en) * 2019-03-20 2020-09-24 Foundation For Neglected Disease Research Benzimidazoles derivatives as anti-tuberculosis agents
CN111393435A (zh) * 2020-03-16 2020-07-10 青岛吉澳医药科技有限公司 氮杂吲哚酰胺类化合物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113606A1 (en) * 2010-03-18 2011-09-22 Institut Pasteur Korea Anti-infective compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
UA99729C2 (en) * 2007-08-10 2012-09-25 Х. Луннбек А/С Heteroaryl amide analogues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113606A1 (en) * 2010-03-18 2011-09-22 Institut Pasteur Korea Anti-infective compounds

Also Published As

Publication number Publication date
CN105636646B (zh) 2017-12-19
WO2015009525A1 (en) 2015-01-22
CA2918487A1 (en) 2015-01-22
EP3021947B1 (en) 2017-08-23
KR102301753B1 (ko) 2021-09-15
CN105636646A (zh) 2016-06-01
BR112016000712A2 (pt) 2022-03-22
US20150025087A1 (en) 2015-01-22
AU2014290598A1 (en) 2016-02-11
EA201690227A1 (ru) 2016-07-29
ES2644025T3 (es) 2017-11-27
JP2016530242A (ja) 2016-09-29
JP6366709B2 (ja) 2018-08-01
EA028611B1 (ru) 2017-12-29
KR20160058757A (ko) 2016-05-25
EP3021947A1 (en) 2016-05-25
CA2918487C (en) 2021-08-03
US9163020B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
AU2014290598B2 (en) Azaindole compounds, synthesis thereof, and methods of using the same
US20240207300A1 (en) Combination therapies including myt1 inhibitors
TWI694076B (zh) 三唑并嘧啶化合物及其用途
US20250270197A1 (en) Ribocil c antibiotics effective for gram-negative pathogens
US10822339B2 (en) Pyrrolopyrimidine five-membered azacyclic derivative and application thereof
TWI580668B (zh) B型肝炎抗病毒劑
CN113660931B (zh) 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
EP4233834A2 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
US12479850B2 (en) Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof
KR20160128456A (ko) 이미다조옥사진 화합물에 의한 항종양 효과 증강제
US20220280509A1 (en) Aza-quinoline compounds and uses thereof
US20220204509A1 (en) Pyrimido five-membered heterocyclic compound and use thereof as mutant idh2 inhibitor
US20250127780A1 (en) Imidazo[4,5-b]pyridine and pyrazolo[1,5-a]pyrimidine derivatives as sik modulators for the treatment of rheumatoid arthritis
US11072591B2 (en) Tetrazole compounds and their use in the treatment of tuberculosis
CN110461837A (zh) 新型吡咯并吡啶衍生物、其制备方法及用途
JP2025520237A (ja) ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物
WO2016067009A1 (en) Compounds with activity against bacteria and mycobacteria
EP3250205B1 (en) Benzimidazole sulfide derivatives for the treatment or prevention of tuberculosis
JP2024528073A (ja) 有機ピリジン-ピラゾール化合物及びその使用
CZ309884B6 (cs) Substituovaný purin, jeho použití a farmaceutický přípravek ho obsahující
BR112016000712B1 (pt) Compostos de azaindol, síntese dos mesmos e métodos de uso dos mesmos
US20070213339A1 (en) Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions
JP2025525481A (ja) Tyk2/jak1の阻害剤としてのヘテロアリール化合物、その組成物および適用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)